Caroline Wasén
Biträdande Lektor
E-postadress: caroline.wasen@ki.se
Besöksadress: D2:01, Karolinska Universitetssjukhuset, 17176 Stockholm
Postadress: K2 Medicin, Solna, K2 Reuma Jakobsson P, 171 77 Stockholm
Utvalda publikationer
- Journal article: NATURE COMMUNICATIONS. 2024;15(1):3872Wasen C; Beauchamp LC; Vincentini J; Li S; Leserve DS; Gauthier C; Lopes JR; Moreira TG; Ekwudo MN; Yin Z; da Silva P; Krishnan RK; Butovsky O; Cox LM; Weiner HL
- Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2018;115(51):E12063-E12072Andersson KME; Wasen C; Juzokaite L; Leifsdottir L; Erlandsson MC; Silfversward ST; Stokowska A; Pekna M; Pekny M; Olmarker K; Heckemann RA; Kalm M; Bokarewa MI
Artiklar
- Journal article: MUCOSAL IMMUNOLOGY. 2024;17(5):911-922Moreira TG; Cox LM; Da Silva P; Mangani D; De Oliveira MG; Escobar G; Lanser TB; Murphya L; Lobo ELC; Milsteina O; Gauthiera CD; Guimaraesa AC; Schwerdtfeger L; Ekwudo MN; Wasen C; Liu S; Menezes GB; Ferreira E; Gabriely G; Anderson AC; Faria AMC; Rezende RM; Weiner HL
- Journal article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024;25(17):9379Wieg L; Ciola JC; Wasen CC; Gaba F; Colletti BR; Schroeder MK; Hinshaw RG; Ekwudo MN; Holtzman DM; Saito T; Sasaguri H; Saido TC; Cox LM; Lemere CA
- Journal article: GUT MICROBIOME. 2023;4:E2Boehme M; Guzzetta KE; Wasén C; Cox LM
- Journal article: FRONTIERS IN IMMUNOLOGY. 2022;13:840002Chandrasekaran V; Oparina N; Garcia-Bonete M-J; Wasen C; Erlandsson MC; Malmhall-Bah E; Andersson KME; Jensen M; Silfverswaerd ST; Katona G; Bokarewa MI
- Journal article: ANNALS OF NEUROLOGY. 2021;89(6):1195-1211Cox LM; Maghzi AH; Liu S; Tankou SK; Dhang FH; Willocq V; Song A; Wasen C; Tauhid S; Chu R; Anderson MC; De Jager PL; Polgar-Turcsanyi M; Healy BC; Glanz BI; Bakshi R; Chitnis T; Weiner HL
- Journal article: BMC MEDICINE. 2019;17(1):141Erlandsson MC; Lyngfelt L; Aberg ND; Wasen C; Espino RA; Silfversward ST; Nadali M; Jood K; Andersson KME; Pullerits R; Bokarewa MI
- Article: FRONTIERS IN IMMUNOLOGY. 2018;9:1677Wasen C; Erlandsson MC; Bossios A; Ekerljung L; Malmhall C; Silfversward ST; Pullerits R; Lundback B; Bokarewa MI
- Journal article: INTERNATIONAL UROLOGY AND NEPHROLOGY. 2018;50(4):647-656Wasen C; Ekstrand M; Levin M; Giglio D
- Journal article: AUTOIMMUNITY REVIEWS. 2017;16(8):845-855Gravina G; Wasen C; Garcia-Bonete MJ; Turkkila M; Erlandsson MC; Silfversward ST; Brisslert M; Pullerits R; Andersson KM; Katona G; Bokarewa MI
- Article: JOURNAL OF AUTOIMMUNITY. 2017;78:101-110Wasen C; Turkkila M; Bossios A; Erlandsson M; Andersson KM; Ekerljung L; Malmhall C; Brisslert M; Silfversward ST; Lundback B; Bokarewa MI
- Journal article: CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 2016;43(7):698-705Giglio D; Wasen C; Molne J; Suchy D; Swanpalmer J; Valbuena JJ; Tobin G; Ny L
- Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2015;112(48):E6644-E6653Svensson MND; Andersson KME; Wasen C; Erlandsson MC; Nurkkala-Karlsson M; Jonsson I-M; Brisslert M; Bemark M; Bokarewa MI
- Journal article: AUTONOMIC AND AUTACOID PHARMACOLOGY. 2015;35(3):32-40Winder M; Wasén C; Aronsson P; Giglio D
Forskningsbidrag
- Swedish Research Council1 January 2026 - 31 December 2029Our understanding of how chronic immune activation in RA affects the brain structure is very limited, despite evidence of neurological manifestations of RA. Based on my preliminary data demonstrating atrophy in the frontoparietal cortex of RA patients, this project aims to 1) Measure the progression of brain atrophy in RA and its impact on cognition and disability, 2) Identify immune mechanisms driving RA-related brain atrophy and assess whether tumour necrosis factor (TNF) inhibition can prevent it, and 3) Test if neuroinflammation and neuronal loss in mouse models of RA can be blocked with biological disease-modifying anti-rheumatic drugs (bDMARDs).In this project, I will collect and analyse longitudinal data from two cohorts of RA patients, of which one cohort initialized TNF inhibiting treatment at baseline. This includes magnetic resonance imaging to measure brain volume changescognitive and functional tests to measure clinical outcomesingle cell sequencing and protein measurements in serum and cerebrospinal fluid to determine immunological mechanismsand genotyping to identify risk genes. I will also establish protocols for studying neuroinflammation and brain structure changes in RA mouse models, and investigate the effects of peripheral and central administration of bDMARDs.Identifying immune mechanisms of brain atrophy could shift RA treatment approaches to incorporate brain health, which is important to improve cognitive and functional outcomes in RA patients.
